Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 2/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22172089 | 0.92 | FFAR1 (0.48) | FFAR4FFAR1FAAHDPP7GPR84 | |
| SCHEMBL6079300 | 0.92 | FFAR4 (0.44) | FFAR4FFAR1FAAHDPP7GPR84 | |
| SCHEMBL3856822 | 0.86 | GPR84 (0.38) | FFAR4FFAR1FAAHDPP7GPR84 | |
| SCHEMBL27558770 | 0.81 | ALDH1A1 (0.52) | FFAR4FFAR1FAAHDPP7GPR84 | |
| SCHEMBL27900045 | 0.81 | EPHX1 (0.63) | FFAR4FFAR1FAAHDPP7EPHX2 | |
| SCHEMBL28869262 | 0.81 | CASP2 (0.63) | FFAR4FFAR1FAAHDPP7GPR84 | |
| SCHEMBL42439 | 0.80 | — | — | |
| SCHEMBL3772713 | 0.79 | THRB (0.39) | FFAR4FFAR1FAAHGPR84EPHX2 | |
| SCHEMBL6330652 | 0.78 | CYP2D6 (0.43) | — | |
| SCHEMBL28986100 | 0.78 | ACE2 (0.52) | DPP7EPHX1CA2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900243-B2 | Phenylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2005-05-31 | — | — | US | disclosed |
| EP-1263715-B1 | NOVEL PHENYLHETEROALKYLAMINE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-04-28 | — | — | EP | disclosed |
| US-20030065174-A1 | Novel phenylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2003-04-03 | — | — | US | disclosed |
| EP-1263715-A1 | NOVEL PHENYLHETEROALKYLAMINE DERIVATIVES | AstraZeneca AB (SE) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001062714-A1 | NOVEL PHENYLHETEROALKYLAMINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065174-A1 | Novel phenylheteroalkylamine derivatives | OPRK1, NOS2, OPRM1 | FFAR4 339/4885FFAR1 118/4885FAAH 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.